Wen‐Teng Chang
Papers
1
Total Citations
12
H-Index
1
About
Dr. Wen-Teng Chang is a leading surgical oncologist whose research focuses on aggressive treatment strategies for advanced abdominal cancers, particularly peritoneal metastases. His most cited work, a 2020 study on cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastases of hepatocellular carcinoma (HCC-PM), has garnered 12 citations and addresses a critical gap in treating this challenging condition. By demonstrating that this intensive, multimodal approach can achieve meaningful outcomes where conventional therapies often fail, Dr. Chang has helped expand the therapeutic frontier for patients with advanced HCC. His contributions lie in refining patient selection criteria and optimizing perioperative management for CRS/HIPEC, a technically demanding procedure. While his citation count reflects a focused, emerging impact, his work is pivotal for oncologists seeking to improve survival in metastatic liver cancer. Dr. Chang’s research bridges the gap between surgical innovation and clinical application, offering new hope for a patient population with historically poor prognoses.
Research Focus
Key Achievements
Top Papers
- 1